Compare BigBearai Holdings Inc (BBAI) vs Charles River Laboratories Intl. Inc (CRL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BigBearai Holdings Inc vs Charles River Laboratories Intl. Inc — how do they compare? BigBearai Holdings Inc trades at $3.26 (market cap $1.60B), while Charles River Laboratories Intl. Inc trades at $286.31 (market cap $13.46B). The key difference: Charles River Laboratories Intl. Inc is far larger — about 8.4× BigBearai Holdings Inc's market cap, and Charles River Laboratories Intl. Inc is trading nearer its 52-week high, BigBearai Holdings Inc nearer its low. Which is the better fit depends on your goals.
| BBAI | CRL | |
|---|---|---|
Market Cap | $1.60B | $13.46B |
Sector | Technology | Health |
52-Week High | $8.91 | $282.00 |
52-Week Low | $2.61 | $145.57 |
Enterprise Value | $1.30B | $16.30B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BigBear.ai (BBAI) trades at $3.32, up 2.79% with a bullish technical signal. The company reported Q2 2026 revenue growth of 13% but missed EPS expectations. Despite negative profitability metrics (-65.2% net margin), the stock shows institutional interest with 75% analyst hold ratings. Recent news highlights defense contract wins and generative AI platform expansion for Department of War missions.
Outlook remains cautious due to persistent losses and revenue headwinds, though backlog growth and government contracts provide stability. Investment opportunity exists in AI defense specialization, but risks include execution challenges and competitive pressure. The stock requires careful monitoring of profitability improvements and contract execution.
Charles River Laboratories (CRL) trades at $277.00, up 3.56% on the day and near its 52-week high of $277.07, reflecting strong bullish momentum. The stock exhibits positive technical signals with moving averages indicating an uptrend, though oscillators suggest overbought conditions. Fundamentally, the company reported Q2 2026 EPS of $3.02, beating estimates, and raised full-year guidance, yet faces profitability challenges with a negative net income margin of -5.96% and elevated valuation ratios like a P/E of 684.85. Recent news highlights improved biotech demand and institutional buying interest.
The outlook for CRL is cautiously optimistic, driven by earnings beats and raised guidance, but high valuation and weak profitability pose risks. Investment opportunity lies in sustained demand for drug development services, while risks include margin pressure, debt levels, and sensitivity to biotech funding cycles. The stock's proximity to all-time highs warrants monitoring for pullbacks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BigBearai Holdings Inc
BigBearai Holdings Inc is a specialized provider of AI-driven decision intelligence solutions, primarily serving the U.S. defense, intelligence, and national security communities. It operationalizes complex data into actionable insights through its core modules—Observe, Orient, and Dominate—to support mission-critical operations and logistics.
Read more on BBAI →About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →
